A phase II study of lenalidomide in patients with extranodal marginal zone B-cell lymphoma of the mucosa associated lymphoid tissue (MALT lymphoma)

Haematologica

Volumn 98, Issue 3, 2013, Pages 353-356

  Kiesewetter, Barbara ^a   Troch, Marlene ^a   Dolak, Werner ^b   Müllauer, Leonhard ^b   Lukas, Julius ^b   Zielinski, Christoph C ^a   Raderer, Markus ^a  

^a Clinical Division of Oncology   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

LENALIDOMIDE; ANTINEOPLASTIC AGENT; THALIDOMIDE;

ADULT; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTHRALGIA; ARTICLE; BILIARY COLIC; CLINICAL ARTICLE; CONJUNCTIVITIS; CONSTIPATION; COUGHING; DEATH; DESQUAMATION; DIARRHEA; DRUG DOSE REDUCTION; DRUG RESPONSE; DRUG WITHDRAWAL; DRY SKIN; DYSGEUSIA; DYSPNEA; EYE EDEMA; FATIGUE; FEMALE; FEMUR FRACTURE; FEVER; FOLLOW UP; HEADACHE; HEARTBURN; HERPES ZOSTER; HUMAN; INSOMNIA; LEG CRAMP; LEUKOPENIA; LIMB PAIN; LYMPHOCYTOPENIA; MALE; MARGINAL ZONE LYMPHOMA; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PARESTHESIA; PAROTID GLAND DISEASE; PHASE 2 CLINICAL TRIAL; PLEURA EFFUSION; PNEUMONIA; PRURITUS; RASH; THROMBOCYTOPENIA; TREMOR; VERTIGO; VOMITING; ANALOGS AND DERIVATIVES; CANCER STAGING; CLINICAL TRIAL; LYMPHOMA, B-CELL, MARGINAL ZONE; MIDDLE AGED; PATHOLOGY; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; LYMPHOMA, B-CELL, MARGINAL ZONE; MALE; MIDDLE AGED; NEOPLASM STAGING; THALIDOMIDE; TREATMENT OUTCOME;

EID: 84874539200     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2012.065995     Document Type: Article

References (18)

1. Isaacson PG, Chott A, Nakumura S, Müller-Hermelink HK, Harris NL, Swerdlow SH. Extranodal marginal cell lymphoma of mucosa-associated tissue (MALT-lymphoma). In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. WHO classification of tumours of the haematopoietic and lymphoid tissues. IARC: Lyon 2008:214-9.
2. Wöhrer S, Troch M, Streubel B, Hoffmann M, Müllauer L, Chott A, et al. Pathology and clinical course of MALT lymphoma with plasmacytic differentiation. Ann Oncol. 2007;18(12):2020-4.
3. Ruskoné-Fourmestraux A, Fischbach W, Aleman BM, Boot H, Du MQ, Megraud F, et al. EGILS consensus report. Gastric extranodal marginal zone B-cell lymphoma of MALT. Gut. 2011;60(6):747-58.
4. Davies F, Baz R. Lenalidomide mode of action: linking bench and clinical findings. Blood Rev. 2010;24 (Suppl 1):S13-9.
5. Troch M, Zielinski C, and Raderer M. Absence of efficacy of thalidomide monotherapy in patients with extranodal marginal zone B-cell lymphoma of the mucosa associated lymphoid tissue (MALT lymphoma). Ann Oncol. 2009;20(8):1446-7.
6. Kapoor P, Kumar S, Mandrekar SJ, Laumann KM, Dispenzieri A, Lacy MQ, et al. Efficacy of thalidomideor lenalidomide-based therapy in proliferative multiple myeloma. Leukemia. 2011;25(7):1195-7.
7. Gay F, Hayman SR, Lacy MQ, Buadi F, Gertz MA, Kumar S, et al. Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients. Blood. 2010;115(7):1343-50.
8. Guglielmelli T, Bringhen S, Rrodhe S, Gay F, Cavallo F, Berruti A, et al. Previous thalidomide therapy may not affect lenalidomide response and outcome in relapse or refractory multiple myeloma patients. Eur J Cancer. 2011;47(6):814-8.
9. Wiernik PH, Lossos IS, Tuscano JM, Justice G, Vose JM, Cole CE, et al. Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma. J Clin Oncol. 2008;26(30):4952-7.
10. Witzig TE, Wiernik PH, Moore T, Reeder C, Cole C, Justice G, et al. Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin's lymphoma. J Clin Oncol. 2009;27(32):5404-9.
11. Habermann TM, Lossos IS, Justice G, Vose JM, Wiernik PH, McBride K, et al. Lenaliodomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma. Br J Haematol. 2009;145(3):344-9.
12. Witzig TE, Vose JM, Zinzani PL, Reeder CB, Buckstein R, Polikoff JA, et al. An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma. Ann Oncol. 2011;22(7):1622-7.
13. Copie-Bergman C, Gaulard P, Lavergne-Slove A, Brousse N, Fléjou JF, Dordonne K, et al. Proposal for a new histological grading system for post treatment evaluation of gastric lymphoma. Gut. 2003;52(11):1656.
14. Novakowski GS, LaPlant B, Habermann TM, Rivera CE, Macon WR, Inwards DJ, et al. Lenalidomide can be safely combined with R-CHOP (R2CHOP) in the initial chemotherapy for aggressive B-cell lymphomas: phase I study. Leukemia. 2011; 25(12):1877-81.
15. Czuczman M, Vose JM, Witzig TE, Zinzani PL, Buckstein R, Polikoff J, et al. The differential effect of lenalidomide monotherapy in patients with relapsed or refractory transformed non-Hodgkin's lymphoma of distinct histological origin. Br J Haematol. 2011;154(4):477-81.
16. Hernandez-Ilizaliturri FJ, Deeb G, Zinzani PL, Pileri SA, Malik F, Macon WR, et al. Higher response to lenalidomide in relapsed/refractory diffuse large B-cell lymphoma in non-germinal center B-cell like than in germinal center B-cell like phenotype. Cancer. 2011;117(22):5058-66.
17. Chanan-Khan A, Miller KC, Musial L, Lawrence D, Padmanabhan S, Takeshita K, et al. Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study. J Clin Oncol. 2006;24(34):5343-9.
18. Ferrajoli A, Lee BN, Schlette EJ, O'Brien SM, Gao H, Wen S, et al. Lenalidomide induces complete and partial remissions in patients with relapsed and chronic lymphocytic leukemia. Blood. 2008;111(11):5291-7.